Shimon Citron - 30 Jun 2022 Form 3 Insider Report for Artemis Therapeutics, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Shimon Citron
Issuer symbol: N/A
Transactions as of: 30 Jun 2022
Net transactions value: $0
Form type: 3
Filing time: 12 Aug 2022, 16:05:40 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ATMS	Common Stock						15,665,690	30 Jun 2022	Direct
holding	ATMS	Common Stock						10,443,793	30 Jun 2022	By Spouse	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ATMS	Series D Preferred Stock							30 Jun 2022	Common Stock	32,772,000		Direct	F2, F3, F4
holding	ATMS	Series D Preferred Stock							30 Jun 2022	Common Stock	21,848,400		By Spouse	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are beneficially owned by Mr. Citron's spouse, Sigal Citron. Mr. Citron disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F2	Upon the Issuer's increase of its authorized shares of Common Stock, expected in September 2022, all shares of Series D Preferred Stock will automatically convert into the Issuer's Common Stock.
F3	The Series D Preferred Stock has no expiration date.
F4	Each share of Series D Preferred Stock will convert into 600 shares of the Issuer's Common Stock.